Spots Global Cancer Trial Database for hormone receptor positive malignant neoplasm of breast
Every month we try and update this database with for hormone receptor positive malignant neoplasm of breast cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Prospective Thinking in Hormone-Responsive Breast Cancer | NCT03594578 | Hormone Recepto... | Episodic future... Episodic recent... | 18 Years - 80 Years | Virginia Polytechnic Institute and State University | |
| PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score | NCT01617954 | Hormone Recepto... | MammaPrint | 18 Years - 90 Years | Agendia | |
| Comparison of the Breast Tumor Microenvironment | NCT03165487 | Triple Negative... Hormone Recepto... | Breast tissue c... Blood sample co... | 50 Years - | Columbia University | |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | NCT06120283 | Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ... | BGB-43395 Fulvestrant Letrozole | 18 Years - | BeiGene | |
| Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer | NCT01589367 | Hormone Recepto... | Metformin Placebo | 18 Years - 80 Years | Seoul National University Hospital | |
| Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer | NCT03045653 | Breast Cancer M... | Tamoxifen Oral ... | 18 Years - 70 Years | Sun Yat-sen University | |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer | NCT04030507 | Breast Cancer HER2-positive B... Triple Negative... Hormone Recepto... Inflammatory Br... Metastatic Brea... | MRI | 18 Years - | Dana-Farber Cancer Institute | |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane | NCT02109913 | Hormone Recepto... Metastatic Brea... | Everolimus plus... | 18 Years - | Amsterdam UMC, location VUmc | |
| Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer | NCT03088527 | Hormone Recepto... | RAD140 | 18 Years - | Stemline Therapeutics, Inc. | |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane | NCT02109913 | Hormone Recepto... Metastatic Brea... | Everolimus plus... | 18 Years - | Amsterdam UMC, location VUmc | |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | NCT04088110 | Breast Cancer F... HER2-positive B... Hormone Recepto... Metastatic Brea... Breast Diseases Hormone Recepto... | Pyrotinib Trastuzumab Aromatase Inhib... | 18 Years - 70 Years | Fuzhou General Hospital | |
| PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score | NCT01617954 | Hormone Recepto... | MammaPrint | 18 Years - 90 Years | Agendia | |
| The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population | NCT02347449 | Hormone Recepto... | Questionnaires,... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. | NCT04483505 | Breast Cancer M... Hormone Recepto... | Combination, Ro... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population | NCT02347449 | Hormone Recepto... | Questionnaires,... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer | NCT02025712 | Hormone Recepto... | Exemestane Everolimus | 18 Years - | Organisation for Oncology and Translational Research | |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. | NCT04483505 | Breast Cancer M... Hormone Recepto... | Combination, Ro... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | NCT06120283 | Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ... | BGB-43395 Fulvestrant Letrozole | 18 Years - | BeiGene | |
| Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer | NCT01589367 | Hormone Recepto... | Metformin Placebo | 18 Years - 80 Years | Seoul National University Hospital | |
| Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer | NCT04088032 | Breast Cancer F... Locally Advance... Hormone Recepto... | Abemaciclib, du... | 18 Years - | Stony Brook University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
